People
Athira investor Richard Kayne appears to be making a strong push for Dr. Ronald Krall, former chief medical officer of GlaxoSmithKline, to run the company, despite protests from Athira’s board.
BioSpace sat down with Sven Kili, 2022 ISCT Annual Meeting co-chair, to preview the event, which will focus on 4 key subject areas including launch and commercialization of cell and gene therapies.
David Sabatini has withdrawn his name for consideration for a faculty post at New York University Langone Health.
Biogen announced the leadership change in its quarterly financial report. Michel Vounatsos plans to depart the company when a new CEO is found.
Humacyte’s engineered blood vessels, human acellular vessels, are in a position to take tissue regeneration from a laboratory possibility to a commercial reality.
What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules. The company has 14 small molecule drugs in development.
Emergent BioSolutions Founder and former chief executive officer Fuad El-Hibri has died, the company reported.
Pfizer vaccine head Kathrin Jansen is stepping down from the pharma giant after spearheading the development of the COVID-19 vaccine Comirnaty.
Since its $63 billion acquisition of Allergan in 2019, AbbVie has become one of the leading companies developing therapies for migraine.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES